



an Open Access Journal by MDPI

## Malignant and Potentially Malignant Disorders of the Oral Cavity: Updates from Pathogenesis to Therapy

Guest Editors:

**Dr. Lia Rimondini**

Department of Health Sciences,  
University of Piemonte Orientale  
"UPO", Vercelli, Italy

**Dr. Elena Varoni**

Department of Biomedical,  
Surgical and Dental Sciences,  
Università degli Studi di Milano,  
Milan, Italy

Deadline for manuscript  
submissions:

**closed (31 December 2020)**

### Message from the Guest Editors

Dear Colleagues,

This Special Issue "Malignant and Potentially Malignant Disorders of the Oral Cavity: Updates from Pathogenesis to Therapy" will focus on pathophysiology, diagnosis, prognosis and therapy of malignant and potentially malignant disorders of the oral cavity, but not limited to only these aspects.

It is open to both clinical and pre-clinical research, in a multi-disciplinary approach, and covers both original articles and reviews.

Oral conditions and their associations with other systemic malignant and chronic inflammatory diseases will be considered as well.



[mdpi.com/si/19289](https://mdpi.com/si/19289)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI